MET and non-small cell lung carcinoma: MET inhibitors, such as savolitinib, capmatinib, tepotinib, and crizotinib, have yielded tangible clinical outcomes in osimertinib-resistant NSCLC patients harboring MET amplification in TATTON (NCT02143466), SAVANNAH (NCT03778229), and INSIGHT2 (NCT03940703)[67-69].